Immunotherapy shows promise against mouth precancers
NCT ID NCT02882282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug pembrolizumab (Keytruda) in 15 people with high-risk precancerous mouth lesions. The goal was to see if the drug could prevent these lesions from turning into oral cancer. Participants were randomly assigned to receive the drug or just be watched. The study looked at how long people stayed cancer-free and overall survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CAVITY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single drink reveal how alcohol triggers oral cancer?
- Can heat boost chemo? early trial tests thermotherapy for head and neck cancer
- New pastille could change head and neck cancer treatment
- Could a common diabetes drug stop oral cancer before it starts?
- New proton beam therapy aims to zap head and neck cancer with fewer side effects
- Could skipping the flap during radiation reduce side effects without harming cancer control?